A snapshot of plasma metabolites in first-episode schizophrenia: A capillary electrophoresis time-of-flight mass spectrometry study

Translational Psychiatry

Volumn 4, Issue , 2014, Pages 1-8

  Koike, S ^a,b   Bundo, M ^a   Iwamoto, K ^a   Suga, M ^a   Kuwabara, H ^a   Ohashi, Y ^c   Shinoda, K ^c   Takano, Y ^a   Iwashiro, N ^a   Satomura, Y ^a   Nagai, T ^a   Natsubori, T ^a   Tada, M ^a   Yamasue, H ^a,d   Kasai, K ^a,d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF TOKYO   (Japan)

^c Keio University and Human Metabolome Technologies Inc   (Japan)

^d JAPAN SCIENCE AND TECHNOLOGY AGENCY   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

BENZODIAZEPINE DERIVATIVE; BENZOIC ACID; BETAINE; BIOLOGICAL MARKER; BIPERIDEN; CHLORPROMAZINE; CREATINE; CREATINE KINASE; DIAZEPAM; GLUCONIC ACID; GLUTAMIC ACID; HOMOCYSTEINE; NEUROLEPTIC AGENT; NONANOIC ACID; PERILLIC ACID; CYCLOHEXYLAMINE; DRUG METABOLITE; IMIDAZOLELACTIC ACID; UNCLASSIFIED DRUG;

ADULT; ARTICLE; AUTISM; CAPILLARY ELECTROPHORESIS TIME OF FLIGHT MASS SPECTROMETRY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; FIRST EPISODE SCHIZOPHRENIA; FOLLOW UP; HUMAN; HUMAN TISSUE; MALE; MASS SPECTROMETRY; OUTCOME ASSESSMENT; OXIDATIVE STRESS; POSITIVE AND NEGATIVE SYNDROME SCALE; SCHIZOPHRENIA; BLOOD; CAPILLARY ELECTROPHORESIS; METABOLISM; PLASMA; PROCEDURES; YOUNG ADULT; BLOOD SAMPLING; PSYCHOPHARMACOTHERAPY; TIME OF FLIGHT MASS SPECTROMETRY;

ADULT; BIOLOGICAL MARKERS; CHILD DEVELOPMENT DISORDERS, PERVASIVE; ELECTROPHORESIS, CAPILLARY; FEMALE; HUMANS; MALE; MASS SPECTROMETRY; PLASMA; SCHIZOPHRENIA; YOUNG ADULT;

EID: 84898439884     PISSN: None     EISSN: 21583188     Source Type: Journal    
DOI: 10.1038/tp.2014.19     Document Type: Article

References (58)

1. Global burden of disease. WHO, 2004. At http://www.who.int/topics/global burdenofdisease/en/.
2. Salomon JA, Vos T, Hogan DR, Gagnon M, Naghavi M, Mokdad A et al. Common values in assessing health outcomes from disease and injury: disability weights measurement study for the Global Burden of Disease Study 2010. Lancet 2012; 380: 2129-2143.
3. Meyer-Lindenberg A. From maps to mechanisms through neuroimaging of schizophrenia. Nature 2010; 468: 194-202.
4. Cai HL, Li HD, Yan XZ, Sun B, Zhang Q, Yan M et al. Metabolomic analysis of biochemical changes in the plasma and urine of first-episode neuroleptic-naive schizophrenia patients after treatment with risperidone. J Proteome Res 2012; 11: 4338-4350.
5. Yang J, Chen T, Sun L, Zhao Z, Qi X, Zhou K et al. Potential metabolite markers of schizophrenia. Mol Psychiatry 2011; 18: 67-78.
6. Meyer JM, Stahl SM. The metabolic syndrome and schizophrenia. Acta Psychiatr Scand 2009; 119: 4-14.
7. Oresic M, Tang J, Seppanen-Laakso T, Mattila I, Saarni SE, Saarni SI et al. Metabolome in schizophrenia and other psychotic disorders: a general populationbased study. Genome Med 2011; 3: 19.
8. Herberth M, Koethe D, Cheng TM, Krzyszton ND, Schoeffmann S, Guest PC et al. Impaired glycolytic response in peripheral blood mononuclear cells of first-onset antipsychotic-naive schizophrenia patients. Mol Psychiatry 2011; 16: 848-859.
9. Perkins DO, Gu H, Boteva K, Lieberman JA. Relationship between duration of untreated psychosis and outcome in first-episode schizophrenia: a critical review and meta-analysis. Am J Psychiatry 2005; 162: 1785-1804. (Pubitemid 41428609)
10. Bertolote J, McGorry P. Early intervention and recovery for young people with early psychosis: consensus statement. Br J Psychiatry Suppl 2005; 48: s116-s119. (Pubitemid 41139677)
11. Solomon M, Olsen E, Niendam T, Ragland JD, Yoon J, Minzenberg M et al. From lumping to splitting and back again: atypical social and language development in individuals with clinical-high-risk for psychosis, first episode schizophrenia, and autism spectrum disorders. Schizophr Res 2011; 131: 146-151.
12. Kuwabara H, Yamasue H, Koike S, Inoue H, Kawakubo Y, Kuroda M et al. Altered metabolites in the plasma of autism spectrum disorder: a capillary electrophoresis time-of-flight mass spectroscopy study. PLoS One 2013; 8: e73814.
13. Barneveld PS, Pieterse J, de Sonneville L, van Rijn S, Lahuis B, van Engeland H et al. Overlap of autistic and schizotypal traits in adolescents with Autism Spectrum Disorders. Schizophr Res 2011; 126: 231-236.
14. Koike S, Takizawa R, Nishimura Y, Takano Y, Takayanagi Y, Kinou M et al. Different hemodynamic response patterns in the prefrontal cortical sub-regions according to the clinical stages of psychosis. Schizophr Res 2011; 132: 54-61.
15. McGorry PD, Hickie IB, Yung AR, Pantelis C, Jackson HJ. Clinical staging of psychiatric disorders: a heuristic framework for choosing earlier, safer and more effective interventions. Aust N Z J Psychiatry 2006; 40: 616-622. (Pubitemid 43984963)
16. Holmes E, Tsang TM, Huang JT, Leweke FM, Koethe D, Gerth CW et al. Metabolic profiling of CSF: evidence that early intervention may impact on disease progression and outcome in schizophrenia. PLoS Med 2006; 3: e327.
17. Yao JK, Dougherty GG Jr, Reddy RD, Keshavan MS, Montrose DM, Matson WR et al. Altered interactions of tryptophan metabolites in first-episode neuroleptic-naive patients with schizophrenia. Mol Psychiatry 2010; 15: 938-953.
18. Soga T, Baran R, Suematsu M, Ueno Y, Ikeda S, Sakurakawa T et al. Differential metabolomics reveals ophthalmic acid as an oxidative stress biomarker indicating hepatic glutathione consumption. J Biol Chem 2006; 281: 16768-16776.
19. Sato S, Soga T, Nishioka T, Tomita M. Simultaneous determination of the main metabolites in rice leaves using capillary electrophoresis mass spectrometry and capillary electrophoresis diode array detection. Plant J 2004; 40: 151-163. (Pubitemid 39342602)
20. Soga T, Ohashi Y, Ueno Y, Naraoka H, Tomita M, Nishioka T. Quantitative metabolome analysis using capillary electrophoresis mass spectrometry. J Proteome Res 2003; 2: 488-494. (Pubitemid 37376843)
21. Soga T, Sugimoto M, Honma M, Mori M, Igarashi K, Kashikura K et al. Serum metabolomics reveals gamma-glutamyl dipeptides as biomarkers for discrimination among different forms of liver disease. J Hepatol 2011; 55: 896-905.
22. Hirayama A, Kami K, Sugimoto M, Sugawara M, Toki N, Onozuka H et al. Quantitative metabolome profiling of colon and stomach cancer microenvironment by capillary electrophoresis time-of-flight mass spectrometry. Cancer Res 2009; 69: 4918-4925.
23. Koike S, Takano Y, Iwashiro N, Satomura Y, Suga M, Nagai T et al. A multimodal approach to investigate biomarkers for psychosis in a clinical setting. Schizophr Res 2013; 143: 116-124.
24. American Psychiatric Association (APA). Practice guideline for the treatment of patients with schizophrenia. Am J Psychiatry 1997; 154: 1-63.
25. Lieberman JA, Tollefson GD, Charles C, Zipursky R, Sharma T, Kahn RS et al. Antipsychotic drug effects on brain morphology in first-episode psychosis. Arch Gen Psychiatry 2005; 62: 361-370. (Pubitemid 40471685)
26. Sheehan DV, Lecrubier Y, Sheehan KH, Amorim P, Janavs J, Weiller E et al. The Mini-International Neuropsychiatric Interview (M.I.N.I.): the development and validation of a structured diagnostic psychiatric interview for DSM-IV and ICD-10. J Clin Psychiatry 1998; 59(Suppl 20): 22-33, quiz 4-57.
27. American Psychiatric Association (APA). Diagnostic and Statistical Manual of Mental Disorders 4th edn. American Psychiatric Press: Washington, D.C. USA, 1994.
28. Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull 1987; 13: 261-276. (Pubitemid 18039085)
29. Watanabe T, Yahata N, Abe O, Kuwabara H, Inoue H, Takano Y et al. Diminished medial prefrontal activity behind autistic social judgments of incongruent information. PLoS One 2012; 7: e39561.
30. Aoki Y, Abe O, Yahata N, Kuwabara H, Natsubori T, Iwashiro N et al. Absence of age-related prefrontal NAA change in adults with autism spectrum disorders. Transl Psychiatry 2012; 2: e178.
31. Lord C, Rutter M, Le Couteur A. Autism Diagnostic Interview-Revised: a revised version of a diagnostic interview for caregivers of individuals with possible pervasive developmental disorders. J Autism Dev Disord 1994; 24: 659-685. (Pubitemid 24309810)
32. Ooga T, Sato H, Nagashima A, Sasaki K, Tomita M, Soga T et al. Metabolomic anatomy of an animal model revealing homeostatic imbalances in dyslipidaemia. Mol Biosyst 2011; 7: 1217-1223.
33. Baran R, Kochi H, Saito N, Suematsu M, Soga T, Nishioka T et al. MathDAMP: a package for differential analysis of metabolite profiles. BMC Bioinformatics 2006; 7: 530.
34. Ohashi Y, Hirayama A, Ishikawa T et al. Depiction of metabolome changes in histidine-starved Escherichia coli by CE-TOFMS. Mol Biosyst 2008; 4: 135-147.
35. Sreekumar A, Poisson LM, Rajendiran TM, Khan AP, Cao Q, Yu J et al. Metabolomic profiles delineate potential role for sarcosine in prostate cancer progression. Nature 2009; 457: 910-914.
36. Ueland PM. Choline and betaine in health and disease. J Inherit Metab Dis 2011; 34: 3-15.
37. Benevenga NJ. Consideration of betaine and one-carbon sources of N5- methyltetrahydrofolate for use in homocystinuria and neural tube defects. Am J Clin Nutr 2007; 85: 946-949. (Pubitemid 46557906)
38. Peerbooms OL, van Os J, Drukker M, Kenis G, Hoogveld L, de Hert M et al. Metaanalysis of MTHFR gene variants in schizophrenia, bipolar disorder and unipolar depressive disorder: evidence for a common genetic vulnerability? Brain Behav Immun 2011; 25: 1530-1543.
39. Ford AH, Flicker L, Hankey GJ, Norman P, van Bockxmeer FM, Almeida OP. Homocysteine methylenetetrahydrofolate reductase C677T polymorphism and cognitive impairment: the health in men study. Mol Psychiatry 2012; 17: 559-566.
40. Tsai JC, Perrella MA, Yoshizumi M, Hsieh CM, Haber E, Schlegel R et al. Promotion of vascular smooth muscle cell growth by homocysteine: a link to atherosclerosis. Proc Natl Acad Sci USA 1994; 91: 6369-6373. (Pubitemid 24200662)
41. Freeman JM, Finkelstein JD, Mudd SH. Folate-responsive homocystinuria and schizophrenia. A defect in methylation due to deficient 5,10- methylenetetrahydrofolate reductase-activity. N Engl J Med 1975; 292: 491-496.
42. Susser E, Brown AS, Klonowski E, Allen RH, Lindenbaum J. Schizophrenia and impaired homocysteine metabolism: a possible association. Biol Psychiatry 1998; 44: 141-143. (Pubitemid 28305534)
43. Smolin LA, Benevenga NJ, Berlow S. The use of betaine for the treatment of homocystinuria. J Pediatr 1981; 99: 467-472. (Pubitemid 11029956)
44. Frosst P, Blom HJ, Milos R, Goyette P, Sheppard CA, Matthews RG et al. A candidate genetic risk factor for vascular disease: a common mutation in methylenetetrahydrofolate reductase. Nat Genet 1995; 10: 111-113.
45. Shinohara Y, Hasegawa H, Tagoku K, Hashimoto T. Simultaneous determination of methionine and total homocysteine in human plasma by gas chromatographymass spectrometry. J Chromatogr B Biomed Sci Appl 2001; 758: 283-288. (Pubitemid 32524024)
46. Arinami T, Yamada N, Yamakawa-Kobayashi K, Hamaguchi H, Toru M. Methylenetetrahydrofolate reductase variant and schizophrenia/depression. Am J Med Genet 1997; 74: 526-528. (Pubitemid 27424220)
47. Yoshimi A, Aleksic B, Kawamura Y, Takahashi N, Yamada S, Usui H et al. Gene-wide association study between the methylenetetrahydrofolate reductase gene (MTHFR) and schizophrenia in the Japanese population, with an updated metaanalysis on currently available data. Schizophr Res 2010; 124: 216-222.
48. Chang P, Orabi B, Deranieh RM, Dham M, Hoeller O, Shimshoni JA et al. The antiepileptic drug valproic acid and other medium-chain fatty acids acutely reduce phosphoinositide levels independently of inositol in Dictyostelium. Dis Model Mech 2012; 5: 115-124.
49. Williams RS, Cheng L, Mudge AW, Harwood AJ. A common mechanism of action for three mood-stabilizing drugs. Nature 2002; 417: 292-295. (Pubitemid 34534711)
50. Ohnuma T, Arai H. Significance of NMDA receptor-related glutamatergic amino acid levels in peripheral blood of patients with schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2011; 35: 29-39.
51. Maeshima H, Ohnuma T, Sakai Y, Shibata N, Baba H, Ihara H et al. Increased plasma glutamate by antipsychotic medication and its relationship to glutaminase 1 and 2 genotypes in schizophrenia-Juntendo University Schizophrenia Projects (JUSP). Prog Neuropsychopharmacol Biol Psychiatry 2007; 31: 1410-1418. (Pubitemid 47302552)
52. Hashimoto K, Fukushima T, Shimizu E, Komatsu N, Watanabe H, Shinoda N et al. Decreased serum levels of D-serine in patients with schizophrenia: evidence in support of the N-methyl-D-aspartate receptor hypofunction hypothesis of schizophrenia. Arch Gen Psychiatry 2003; 60: 572-576. (Pubitemid 36682314)
53. Tortorella A, Monteleone P, Fabrazzo M, Viggiano A, De Luca L, Maj M. Plasma concentrations of amino acids in chronic schizophrenics treated with clozapine. Neuropsychobiology 2001; 44: 167-171. (Pubitemid 33036026)
54. Alfredsson G, Wiesel FA. Relationships between clinical effects and monoamine metabolites and amino acids in sulpiride-treated schizophrenic patients. Psychopharmacology (Berl) 1990; 101: 324-331. (Pubitemid 20193369)
55. Palomino A, Gonzalez-Pinto A, Aldama A, González-Gómez C, Mosquera F, González- García G et al. Decreased levels of plasma glutamate in patients with firstepisode schizophrenia and bipolar disorder. Schizophr Res 2007; 95: 174-178. (Pubitemid 47313648)
56. Cai HL, Zhu RH, Li HD, Zhang XH, Hu L, Yang W et al. Elevated plasma gammaaminobutyrate/ glutamate ratio and responses to risperidone antipsychotic treatment in schizophrenia. Prog Neuropsychopharmacol Biol Psychiatry 2010; 34: 1273-1278.
57. Melkersson K. Serum creatine kinase levels in chronic psychosis patients-a comparison between atypical and conventional antipsychotics. Prog Neuropsychopharmacol Biol Psychiatry 2006; 30: 1277-1282.
58. Hermesh H, Stein D, Manor I, Shechtmann T, Blumensohn R, Meged S et al. Serum creatine kinase levels in untreated hospitalized adolescents during acute psychosis. J Am Acad Child Adolesc Psychiatry 2002; 41: 1045-1053. (Pubitemid 38338052)